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Abstract 
Introduction: Although the TSH-receptor antibody (TRAb) plays a central role in the pathogenesis of Graves’ disease (GD), the associa-
tion between TRAb at first diagnosis and clinical and laboratory parameters is not well known. On the other hand, a minority of patients 
with GD may be TRAb negative, and there is a lack of adequate evidence to demonstrate the clinical and laboratory characteristics of 
these patients. Therefore, we aimed to investigate the association of TRAb at the initial diagnosis of GD with the clinical and laboratory 
parameters in a large number of patients with GD and to compare the clinical and laboratory parameters between patients with high 
TRAb levels and TRAb-negative patients.
Material and methods: This study included 440 patients [326 (74%) female, 114 (26%) male]. All patients were classified according to 
gender, age, smoking habit, and TRAb levels.
Results: TRAb levels were significantly higher in male compared to female patients and in smokers compared to non-smokers. Smok-
ing male patients had the highest TRAb levels. In regression analysis, goiter size, male gender, cigarette smoking, Graves’ orbitopathy, 
fT3, and anti-TPO antibody levels were independently associated with high TRAb levels, while age at diagnosis and fT4 levels were not 
independently associated with high TRAb levels. TRAb-negative GD was diagnosed in 80 (18%) patients. TRA-negative patients had 
markedly less severe clinical and laboratory hyperthyroidism compared to patients with high TRAb levels. Moreover, the smoking habit 
was significantly lower in patients with TRAb-negative GD.
Conclusions: According to our study results, TRAb levels at the initial diagnosis of GD are differently associated with clinical and labo-
ratory parameters. Male patients and smoking patients with GD tended to have markedly higher TRAb levels and more severe clinical 
hyperthyroidism. Therefore, besides other contributing factors, male gender and smoking may affect TRAb levels and consequently the 
severity of hyperthyroidism in patients with GD. Furthermore, male gender and smoking may have a synergistic effect on TRAb levels 
and consequently on the severity of hyperthyroidism in patients with GD. (Endokrynol Pol 2021; 72 (1): 14–21)
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Introduction
Graves’ disease (GD) is a chronic autoimmune disease 
of the thyroid gland with an incidence of 21 cases per 
100,000 per year and is characterized by diffuse goiter, 
hyperthyroidism, Graves’ orbitopathy (GO), and rarely 
by localized dermopathy and thyroid acropachy [1, 2]. 
Although the pathogenesis of GD is not fully under-
stood, the hyperthyroidism and goiter in GD are related 
to the TSH-receptor antibody (TRAb), which binds to 
and activates the TSH receptors (TSHR) on the surface 
of the follicular thyroid cells [3]. 
Although the measurement of TRAb is the easiest 
way to diagnose GD accurately, in recent American 
Thyroid Association (ATA) and European Thyroid 
Association (ETA) Guidelines for the management of 
hyperthyroidism, measurement of TRAb levels at first 
admission is not routinely suggested in all patients with 
GD and is only suggested in patients with thyrotoxicosis 
in whom a differential diagnosis could not be accurately 
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the present study, we aimed to investigate the associa-
tion of TRAb at the initial diagnosis of GD with clinical 
and laboratory parameters in a large number of patients 
with GD and to compare the clinical and laboratory 
parameters between patients with high TRAb levels 
and TRAb-negative GD as well.
Material and methods
Patients
This retrospective study included 440 patients [326 (74%) female, 
114 (26%) male] who were newly diagnosed with GD from Janu-
ary 2015 through January 2020 in a tertiary endocrinology referral 
center. Patients under treatment with antithyroid drugs, patients 
with a previous history of GD, patients < 17 years old, patients with 
a prior history of radioiodine ablation therapy or thyroidectomy, 
pregnant patients with hyperthyroidism of any kind, patients 
with amiodarone-induced hyperthyroidism, patients with toxic 
multinodular goiter and toxic adenoma, patients with any kind 
of thyroiditis, and patients in whom the exact cause of hyperthy-
roidism could not be determined were not included in the study.
Graves’ disease with high TRAb levels was defined as previously 
reported [11]. In brief, GD with high TRAb levels was diagnosed 
according to clinical hyperthyroidism with or without extrathy-
roidal manifestations associated with a suppressed serum levels 
of thyroid-stimulating hormone (TSH), elevated serum of free 
thyroxine (fT4), and/or free tri-iodothyronine (fT3) levels, a diffuse 
hypoechoic ultrasonographic appearance of the thyroid gland, and 
high TRAb titers. Nevertheless, TRAb-negative GD was diagnosed 
according to the clinical and biochemical findings of hyperthyroid-
ism associated with a high uptake of 99mTc pertechnetate, in which 
a diffuse thyroid overactivity with a homogeneous distribution 
of the radiotracer and a decreased uptake in salivary glands were 
accepted as diagnostic for GD, elevated thyroid gland vascularity 
on color-Doppler ultrasonography and/or assessment of the infe-
rior thyroid artery peak-systolic velocity by color-flow Doppler 
ultrasonography [15,18], the presence of anti-thyroid peroxidase 
(anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies, history of 
other autoimmune diseases, family history of autoimmune thyroid 
disease, follow-up data (relapse after antithyroid drug treatment, 
and TRAb levels after relapse), and exclusion of the other causes of 
hyperthyroidism stated above. The study protocol was approved 
by the Local Ethics Committee.
Clinical and laboratory data
All clinical and laboratory data of the patients were obtained 
through the computer records of our center. The following data of 
the patients at first admission were recorded: gender, age, serum 
TRAb, TSH, fT3, fT4, anti-TPO, and anti-thyroglobulin (anti-TG) 
antibody levels, goiter size by palpation according to the WHO 
classification (0–III), smoking status (yes and no) and GO. In the 
case of missing data, we complemented missing data by phone calls 
to patients. GO in this study was classified according to Werner’s 
criteria as absent (class 0–1) or present (class 2–6: the presence of 
inflammatory signs, proptosis, extraocular muscle, and corneal 
involvement) [19]. To assess the TRAb levels according to age, the 
age of the patients was divided as < 40 and ≥ 40 years old, due 
to a higher frequency of relapse observed in patients < 40 years 
old. However, to assess also the possible effect of menopause on 
TRAb levels, the age of the female patients was also divided as < 
50 and ≥ 50 years old. 
After blood withdrawal, samples for the TSH, fT3, ft4, anti-TPO, 
and anti-TG were centrifuged and analyzed while serum samples 
for the measurement of TRAb were stored at –20°C and analyzed 
weekly. Serum TRAb levels were detected using an electrochemi-
luminescence immunoassay method (Cobas e 801 analyzers, Roche 
made based on the clinical and laboratory results [4, 
5]. Therefore, the number of studies evaluating the 
relationship between TRAb and clinical and labora-
tory parameters during the initial diagnosis of GD is 
relatively low. Most of the existing studies focus only 
on the relationship between TRAb and GO.
One of the important clinical factors associated with 
the development of GD, the occurrence of relapse after 
ATD treatment, and the development and severity of 
GO is cigarette smoking [4, 6–8]. Evidence suggests that, 
after total thyroidectomy, TRAb persists for a longer 
time in the sera of smoking patients with GD compared 
to non-smoking patients [9]. Therefore, smoking may 
prolong the half-life of TRAb. However, the answer to 
the question Does smoking have any association with TRAb 
levels at the initial diagnosis of GD? is not clear yet.
Autoimmune diseases are more frequent among 
females. However, some autoimmune diseases such 
as autoimmune hepatitis and systemic lupus erythe-
matosus (SLE) are associated with worse outcomes in 
male patients [10]. Evidence suggests that compared 
to female patients, male patients with GD have more 
severe disease, a higher frequency of GO, and a higher 
frequency of relapse after ATD discontinuation [11]. The 
age of the patient during the first diagnosis is another 
factor associated with the outcome of GD. Patients < 40 
years old at diagnosis have also a higher risk of relapse 
after treatment with ATDs [12, 13]. However, the as-
sociation between gender as well as age with TRAb at 
the initial diagnosis of GD is not well known.
The sensitivity and specificity of TRAb for diagnosis 
of GD differ according to the TRAb detection method. 
The sensitivity and specificity of TRAb measured by 
a third-generation electrochemiluminescence immuno-
assay method for diagnosis of GD have been reported 
to be 96.2% and 95.2%, respectively [14]. However, even 
assessed by a third-generation method, TRAb could be 
lower than cut-off values in 5–10% of the patients with 
GD [15], a condition known as TRAb-negative GD. 
Although TRAb-negative GD is a rare condition, the 
assessment of the TRAb by older laboratory methods 
has generally been associated with negative results 
[16]. On the other hand, TRAb-negative GD patients 
have been demonstrated to have markedly different 
histopathological features compared to patients with 
high TRAb levels [17]. Therefore, TRAb-negative GD 
has been suggested to be a subtype of GD, but due 
to the rarity of the condition, most studies have been 
conducted in a small number of patients, and therefore 
there is a lack of evidence to demonstrate the clinical 
and laboratory characteristics of the patients with 
TRAb-negative GD, and to compare the clinical and 
laboratory parameters between TRAb-negative patients 
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Diagnostics, Mannheim, Germany). This method uses a biotinylated 
mouse monoclonal antibody that binds to the C-terminal moiety 
of the TSH receptor to immobilize solubilized porcine TSH recep-
tor using magnetic microparticles. This capture antibody does not 
interfere with the binding of another monoclonal antibody (M22) to 
the TSHR [14]. TRAb is detected by its ability to inhibit the binding 
of ruthenium-labeled M22 to the TSH receptor. In this study, the 
cut-off value of TRAb for untreated GD was accepted as 1.75 IU/L, 
as recommended by the manufacturer, with a maximum detection 
capacity of 40 IU/mL (inter-and intra-assay coefficient of variation 
< 17.3% and < 10.3%). Serum TSH, fT3, fT4, anti-TPO, and anti-
TG antibody levels were also detected using a chemiluminescence 
immunoassay method (Cobas e 801 analyzers, Roche Diagnostics, 
Mannheim, Germany). The normal reference values and inter- and 
intra-assay coefficient of variations for TSH, fT3, fT4, anti-TPO, and 
anti-TG antibody levels were as follows: 0.27–4.2 µIU/mL (< 7.2% 
and < 3%), 2.0–4.4 pg/mL (< 7.2% and < 6.5%), 0.93–1.7 ng/dL 
(< 78.4 and < 4.3%), 5–600 IU/mL (< 9.5% and < 6.3%), and 10–4000 
IU/mL (< 6.3% and 4.9%), respectively. 
Statistical analysis
PASW Statistics 18 for Windows was used for data input and statisti-
cal analysis. Mean ± standard deviation and frequencies were used 
to state results. The Independent Sample T-test was used for the 
comparison of normally distributed data, and the Mann-Whitney 
U test was used for the comparison of data that did not follow 
a normal distribution. Analysis of variance (ANOVA) followed by 
post-hoc analysis was used for multiple comparisons. c2 analysis 
was used for categorical data comparison. Pearson correlation 
analysis was used to determine the correlation between variables. 
A multiple regression analysis was used to assess the association 
between each clinical and laboratory variable with TRAb. All tests 
were two-tailed and a p-value < 0.05 was considered statistically 
significant. 
Results
A total of 440 patients (326 [74%] female, 114 [26%] 
male; mean age 41.84 ± 13.26 years) were included in 
this study. The clinical and biochemical characteristics of 
the patients as a whole group and according to gender 
are shown in Table 1.
In the present study, when all patients were 
analyzed as a single group, TRAb levels at the initial 
diagnosis were significantly higher in male compared 
to female patients (13.83 ± 12.17 vs. 9.56 ± 10.31 IU/L, 
p < 0.001). As demonstrated in Table 1, compared to 
female patients, male patients at the initial diagnosis 
more commonly had GO, were more often smok-
ers, and tended to have larger goiter sizes. Although 
a mild inverse correlation was found between TRAb 
levels and age (r = 0.10, p = 0.029) when the age of 
the patients was divided as < 40 and ≥ 40 years old, 
TRAb levels were significantly higher in patients < 40 
compared to the patients ≥ 40 years old (12.07 ± 11.43 
vs. 9.45 ± 10.31 IU/L, p = 0.012). Nevertheless, when 
TRAb levels were separately analyzed according to 
age and gender, TRAb levels were only significantly 
Table 1. Clinical and laboratory characteristics of the study participants as a single group and according to gender





Age 41.8 ± 13.26 40.8 ± 12.9 44.6 ± 13.9 0.01
TRAb [IU/L] 10.66 ± 10.97 9.56 ± 10.31 13.83 ± 12.17 < 0.001 
TSH [IU/mL] 0.009 ± 0.047 0.011 ± 0.055 0.006 ± 0.004 0.32
fT3 [pg/mL] 10.95 ± 6.52 10.65 ± 6.17 11.82 ± 7.41  0.09  
fT4 [ng/dL] 3.45 ± 1.73 3.36 ± 1.70 3.70 ± 1.79 0.07
Anti-TPO [IU/mL] 210.1 ± 208.1 197.5 ± 204.7 246.4 ± 214.6 0.03
Anti-TG [IU/mL] 339.5 ± 710.5 338.4 ± 698.1 342.4 ± 747.8 0.96









0 39 (9)  29 (9) 10 (9)  0.05
1 198 (45) 158 (49) 41 (36) 
2 147 (33) 102 (31) 45 (39) 









TRAb — TSH-receptor antibody; TSH — thyroid-stimulating hormone; fT3 — free tri-iodothyronine; fT4 — free thyroxine; anti-TPO — anti-thyroid peroxidase; anti-TG 
— anti-thyroglobulin
Mean ± standard deviation; *the difference between male and female patients.
The laboratory results for anti-TPO and anti-TG were missed in 5 and 11 patients, respectively
Normal reference values: TRAb < 1.75 IU/L, TSH 0.27–4.2 µIU/mL, fT3 2.0–4.4 pg/mL, fT4 0.93–1.7 ng/dL, anti-TPO 0–34 IU/mL, and anti-TG 0–115 IU/mL.
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higher in male patients < 40 compared to the male 
patients > 40 years old (18.48 ± 12.24 vs. 10.44 ± 11.02 
IU/L, p <0.001), while TRAb levels were not signifi-
cantly different between females < 40 and ≥ 40 as well 
as < 50 and ≥ 50 years old (10.09 ± 10.4 vs. 9.07 ± 10.2 
IU/L, p = 0.37 and 9.59 ± 10.27 vs. 9.47 ± 10.46 IU/L, 
p = 0.92, respectively). 
Taking into consideration the smoking habits of 
the patients, TRAb levels at the initial diagnosis were 
significantly higher in smoking patients compared to 
non-smoking patients (12.05 ± 11.61 vs. 9.71 ± 10.42 
IU/L, p = 0.028). However, when TRAb levels were 
analyzed according to the smoking habits in male 
and female patients separately, smoking male pa-
tients had the highest TRAb levels compared to the 
non-smoking male, and smoking and non-smoking 
females (14.96 ± 10.9, 12.2 ± 11.9, 10.3 ± 10.8, and 
9.1 ± 10 IU/L; p = 0.049, p = 0.029, and p = 0.001, re-
spectively). Furthermore, although statistically it did not 
reach significance, in post-hoc analysis, smoking male 
patients < 40 years old had the highest TRAb levels 
compared to smoking males ≥ 40 years old and smoking 
female patients < 40 and ≥ 40 years old (17.2 ± 12.3, 
12.4 ± 11.9, 12 ± 11.7, and 8.5 ± 9.7 IU/L; p = 0.064, 
p = 0.056, and p = 0.003, respectively).
In this study, although a strong linear correlation 
was found between TRAb levels at diagnosis and goiter 
size (r = 0.66, p < 0.001), in post-hoc analysis, TRAb 
levels were significantly higher in patients with grade 3 
compared to the patients with grade 0, 1, and 2 goiters, 
(21.8 ± 12.03, 1.87 ± 1.92, 5.5 ± 5.83, 15.82 ± 11.43 IU/L, 
respectively; p < 0.001 for all comparisons). Weak linear 
correlations were also found between TRAb and fT3, 
fT4, and anti-TPO antibody levels (r = 0.33, p < 0.001, 
r = 0.23, p = 0.01, and r = 0.29, p < 0.001, respectively). 
In regression analysis, goiter size, male gender, GO, 
cigarette smoking, fT3, and anti-TPO antibody levels 
were independently associated with high TRAb levels 
(OR = 6.42, 95% CI: 5.33–7.83, p < 0.001; OR = 2.59, 95% 
CI: 1.53–4.52, p = 0.009; OR = 2.91, 95% CI: 1.01–4.82, 
p = 0.003, OR = 1.27, 95% CI: 1.03–1.56, p = 0.046; 
OR = 3.5, 95% CI: 2.08–10.98, p = 0.004; OR = 11.11, 
95% CI: 7.6–20.12, p < 0.001, respectively), while age at 
diagnosis as well as fT4 levels were not independently 
associated with high TRAb levels (OR = 1.11, 95% CI: 
0.69–1.64, p = 0.29 and OR = 1.13, 95% CI: 1.03–2.53, 
p = 0.37).  
Among the participants, 80 (18%) patients were 
found to have TRAb-negative GD (< 1.75 IU/L). Due to 
the higher frequency of TRAb-negative GD among the 
patients included in our study, all of the patients diag-
nosed as TRAb-negative GD were carefully assessed by 
clinical evaluation, and laboratory and imaging studies 
to avoid a false diagnosis of GD. 99mTc pertechnetate 
uptake was performed in all of these patients, and 76 
patients (95%) had high uptake values, while the re-
maining four patients (5%) had typical color Doppler 
ultrasonography appearances of thyroid inferno (mark-
edly increased vascularity with homogeneous distribu-
tion within the thyroid parenchyma) and an increased 
(> 30 cm/s) inferior thyroid artery peak-systolic velocity 
on color-flow Doppler ultrasonography. Moreover, 39 
(49%) and 29 (37%) of the patients with TRAb-negative 
GD had increased anti-TPO and anti-TG antibody lev-
els, respectively, and 10 (12.5%) patients had a mild GO 
that improved spontaneously. Among the patients with 
TRAb-negative GD, 16 (20%) experienced a relapse dur-
ing the follow-up. TRAb levels became positive (> 1.75 
IU/L) in two patients after relapse, while they remained 
negative (< 1.75 IU/L) in the remaining patients. On 
the other hand, 14% of the TRAb-negative patients had 
a history of another autoimmune disease, including 
rheumatoid arthritis, type-1 diabetes, psoriatic arthritis, 
primary biliary cirrhosis, and vitiligo, and 33% of them 
had a family history of autoimmune thyroid disease. 
As in patients with high TRAb levels, TRAb-negative 
GD was also more common among females compared 
to male patients, while age at the initial diagnosis was 
not different between patients with high TRAb levels 
and TRAb-negative GD (Tab. 2). However, as demon-
strated in Tab. 2, fT3, fT4, anti-TPO, and goiter sizes 
of the patients were significantly different between 
TRAb-negative patients and patients with high TRAb 
levels (p < 0.001, p = 0.001, p < 0.001, and p < 0.001, 
respectively). As shown in Table 2, the smoking habit 
and GO were also more frequent among GD patients 
with high TRAb levels as compared to TRAb-negative 
patients. The difference between clinical and laboratory 
parameters of the GD patients with TRAb-negative 
disease and high TRAb levels are shown in Table 2. 
Conversely, 18 (4%) patients [8 (7%) male and 10 (3%) 
female] had TRAb levels > 40 IU/L. However, although 
the frequency of male patients with TRAb levels > 40 
IU/L was higher than female patients, the number of 
patients with TRAb levels > 40 IU/L was not adequate 
for comparison of clinical and laboratory parameters. 
Discussion
In this study, TRAb levels at the initial diagnosis of GD 
were differently associated with clinical and laboratory 
parameters. TSH-receptor antibody levels were signifi-
cantly higher in male patients, and male patients tended 
to have markedly larger goiter sizes at diagnosis as well 
as more common GO, as compared to female patients. 
Autoimmune diseases are generally more prevalent 
in females than males; however, the severity of each 
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ders [10]. For instance, studies suggest that course of 
some autoimmune diseases such as psoriasis, autoim-
mune hepatitis, SLE, and multiple sclerosis are more 
severe in males compared to females. Although the 
reason is not exactly clear yet, some genetic, environ-
mental, and hormonal causes have been suggested as 
the reasons for the different gender prevalence, and 
a different course of autoimmune disease between 
genders [10]. Although the cause is not clear yet, 
evidence suggests that compared to female patients, 
male patients with GD have a significantly higher 
frequency of relapse after antithyroid drug discontinu-
ation, as well as a more severe disease course [11, 20]. 
In the present study, the male gender was found to be 
a significant independent contributor to TRAb levels 
in patients with GD. However, although TRAb levels 
were significantly higher in younger male patients, 
in regression analysis, age at diagnosis was not found 
to be an independent contributor to TRAb levels. We 
believe that higher TRAb levels observed in male 
patients at the initial diagnosis of GD in our study 
could support the results of prior studies reporting 
a higher frequency of relapse after discontinuation of 
the antithyroid drugs as well as a more severe disease 
course in male patients with GD [11, 12, 20]. 
The risk of developing GD is higher among smok-
ers. Cigarette smoking affects innate and adaptive 
immune systems with both pro-inflammatory and 
immunosuppressive effects, but it is still unknown 
how smoking might enhance immune pathways like T 
helper-2 responses, leading to GD [6]. In a meta-analy-
sis, the odds ratio (OR) of developing GD was 3.3 (95% 
CI: 2.09–5.22) in current smokers compared with 1.41 
(95% CI: 0.77–2.58) in never smokers [8]. Smoking has 
been suggested to have a modifying immunological 
consequence and an adverse impact on the course of 
GD after the withdrawal of antithyroid drug treatment 
[21]. In a study by Yoshioka et al., smoking was associ-
ated with a prolonged half-live of the serum TRAb 
levels after total thyroidectomy in patients with GD [9]. 
Although the underlying mechanism by which smok-
ing contributes to the high serum level of TRAb is not 
clear, smoking might influence cytokine secretion and 
consequently increase TRAb levels [22, 23]. However, 
there is a lack of evidence in terms of the association 
between TRAb levels at the initial diagnosis of GD and 
smoking. In our study, TRAb levels at the initial diag-
nosis were significantly higher in smokers compared 
to non-smokers (12.05 ± 11.61 vs. 9.71 ± 10.42 IU/L, 
p = 0.028), and the highest TRAb level was observed 
in smoking male patients. Moreover, in regression 
analysis, smoking was also found to be an independent 
contributor to TRAb levels. As demonstrated in Table 
1, 59% of the male and 34% of the female patients 
Table 2. The difference between clinical and laboratory characteristics of patients with high TRAb levels and patients 
with TRAb-negative Graves’ disease (GD) 
Variables Patients with high TRAb* 360 (82%)
TRAb-negative patients†
80 (18%) p-value*
Age 41.4 ± 13.03 43.8 ± 14.13 0.14
Gender (female/male) 263/97 (73/27) 63/17 (79/21) 0.18
TRAb [IU/L] 12.81 ± 11.03 0.99 ± 0.43 < 0.001
fT3 [pg/mL] 11.55 ± 6.75 8.25 ± 4.55 < 0.001
fT4 [ng/dL] 3.57 ± 1.78 2.88 ± 1.35 0.001
Anti-TPO [IU/mL] 231.5 ± 213.6 114.4 ± 148.34 < 0.001
Anti-TG [IU/mL] 370.4 ± 748.9 203.7 ± 489.2 0.06







0 16 (4.4) 23 (28.7) < 0.001
1 147 (40.8) 51 (63.7)
2 142 (39.4) 5 (6.3)
3 54 (15) 1 (1.3)





TRAb — TSH-receptor antibody; fT4 — free thyroxine; fT3 — free tri-iodothyronine; anti-TPO — anti-thyroid peroxidase; anti-TG — anti-thyroglobulin
*Patients with TRAb level of > 1.75 IU/L, †patients with TRAb levels < 1.75 IU/L. The laboratory results for anti-TPO and anti-TG were missed in 5 and 11 patients, 
respectively. Normal reference values: TRAb < 1.75 IU/L, TSH 0.27–4.2 µIU/mL, fT3 2.0–4.4 pg/mL, fT4 0.93–1.7 ng/dL, anti-TPO 0–34 IU/mL, and anti-TG 0–115 IU/mL
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were current smokers. Furthermore, 73% of the male 
patients < 40 years old, the group with the highest 
TRAb levels were current smokers compared to 37% 
of the female patients of the same age. Therefore, the 
higher TRAb levels found in younger male patients 
may be related to the higher frequency of smoking 
among these patients. In contrast, some studies could 
not find a relationship between smoking and TRAb. For 
instance, in a retrospective study, Nyirenda et al. could 
not find a difference in TRAb levels between smoking 
and non-smoking patients with GD [24]. Nevertheless, 
it should be emphasized that only 24 patients in their 
study were current smokers. According to our study 
results, cigarette smoking can affect TRAb levels and 
consequently the severity of hyperthyroidism in pa-
tients with GD. Moreover, smoking and male gender 
may have a synergistic effect on TRAb levels as well as 
on the severity of hyperthyroidism in patients with GD.
Most of the patients with GD have a total T3/T4 ratio 
of > 20 [4, 25]. The higher T3 levels in patients with GD 
are thought to be related to activation of type-II deiodin-
ase by TRAb, an enzyme that is abundantly expressed 
in human thyroid tissues [26]. Our study results are in 
line with previous study results. Although a weak linear 
correlation was found between TRAb and fT3 levels, the 
correlation between TRAb and fT4 was even weaker. 
However, in regression analysis, only fT3 levels were 
independently associated with high TRAb levels, and 
therefore this result of our study may explain, in part, 
the higher fT3/fT4 ratio observed in the majority of the 
patients with GD [4, 25]. 
TRAb assays methods have improved over the 
years. The first-generation TRAb assay detects TRAb 
levels in a competition assay in which the patient’s sera 
is mixed with radiolabeled TSH and TRAb competes 
for binding to the TSH receptors in the liquid phase. 
The second-generation TRAb assay improved the sen-
sitivity of the assay by fixing the TSH receptors to the 
bottom of the wells (solid phase), which reduces the 
interference with the labeled TSH. Nowadays, TRAb 
is generally measured by third-generation assays, in 
which TRAb competes with anti-TSH receptor mono-
clonal antibody (M-22) rather than TSH [14]. However, 
as stated previously, even assessed by a third-generation 
method, TRAb could be lower than the predetermined 
cut-off values in 5–10% of patients with GD, a condi-
tion known as TRAb-negative GD [15], and the clinical 
and laboratory characteristics of these patients are not 
fully understood. In a study conducted by Kawai et al., 
TRAb-negative GD patients in whom TRAb remained 
negative throughout treatment with anti-thyroid drugs 
had a markedly lower risk of relapse than patients with 
high TRAb levels at diagnosis and those who become 
TRAb positive during treatment [27]. In another study 
by Kawai et al., TRAb-negative GD patients had mark-
edly different histopathological features as compared 
to GD patients with high TRAb levels [17]. Papillate 
hyperplastic epithelia were significantly less severe, 
and enlarged colloid was less common in patients with 
TRAb-negative GD compared to patients with high 
TRAb levels. Likewise, moderate or marked lympho-
cytic infiltrations were also observed in all patients 
with TRAb-negative GD but were virtually absent 
in patients with high TRAb levels [17]. In a study by 
Mukuta et al., untreated TRAb-negative patients with 
GD had a mild elevation of thyroid hormones, mildly 
elevated 123I uptake, and small goiters as compared to 
patients with high TRAb levels [28]. However, in their 
study, the patients with high TRAb levels used for the 
comparison were randomly selected among a huge 
number of patients with GD [28]. Although in our study 
almost all patients who were TRAb-negative and those 
with high TRAb levels were included, the results are in 
line with those of the study by Mukuta et al. and sug-
gest markedly lower thyroid hormones, anti-TPO, and 
anti-TG antibody levels in patients with TRAb-negative 
GD as compared to GD patients with high TRAb levels 
(Tab. 2). As demonstrated in Tab. 2, our study results also 
suggest that TRAb-negative GD may be a less severe 
subtype of GD with mild to moderate hyperthyroid-
ism, very mild GO in a minority of the patients, and 
smaller goiter sizes, as compared to GD patients with 
high TRAb levels. Although no difference in terms of age 
and gender was found between TRAb-negative patients 
and patients with high TRAb levels, the smoking habit 
was more common among patients with high TRAb 
levels (Tab. 2). This outcome of our study demonstrates 
again that cigarette smoking could affect TRAb levels in 
patients with GD. The high number of TRAb-negative 
patients observed in our study may be due to different 
factors, including the health care system in our coun-
try in which all patients can directly apply to tertiary 
referral centers without being treated in primary care 
health centers. This factor may decrease the number of 
patients with mild disease, particularly TRAb-negative 
cases in referral centers in some parts of the world. An-
other important factor that could be related to a higher 
frequency of TRAb-negative GD in our study is the 
cut-off value of TRAb used in our institution. In the 
present study, the cut-off value of TRAb for untreated 
GD was accepted as 1.75 IU/L, as recommended by the 
manufacturer. In a recent study conducted by Scappat-
iccio et al., the optimal cut-off value for TRAb assessed 
by a second-generation method (Thermo Scientific 
BRAHMS Kryptor) was suggested as 0.7 IU/L (sensitiv-
ity and specificity 93% and 88.8%, respectively), despite 
the manufacturer recommended cut-off value of 1.5 











The association of TRAb with clinical and laboratory parameters in Graves’ disease Sayid Shafi Zuhur et al.
were reported to have TRAb-negative GD, despite using 
a cut-off value of 0.7 IU/L. Although in the recent ETA 
guidelines for the management of Graves’ hyperthyroid-
ism the sensitivity and specificity of TRAb assessed either 
by a second- or a third-generation assay method were 
indicated as 97 and 98%, respectively, they do not sug-
gest any specific cut-off value for TRAb assessed either 
by a second- or a third-generation method [5]. In the 
present study, if a cut-off value of 0.7 IU/L instead of the 
manufacturer recommended cut-off value of 1.75 IU/L 
for TRAb had been used, only 23 patients (5%) would 
have been diagnosed as TRAb-negative GD. Therefore, 
the manufacturer-recommended cut-off value for TRAb 
may not be appropriate for all populations. On the other 
hand, the different genetic backgrounds of our patients 
may also have contributed to the higher frequency of 
TRAb-negative patients. For instance, in a study by Vos 
et al., CTLA4–49 polymorphism was not associated 
with relapse of GD in Dutch patients [13], while it was 
suggested as a risk factor for relapse in Turkish patients 
with GD [30]. However, the exact causes of the higher 
number of TRAb-negative GD in our patients have to 
be investigated further. 
Our study has several limitations. The main limita-
tion of our study is the retrospective design of the study 
that may have caused a selection bias. Therefore, the 
inclusion of some patients with GD may have been 
missed, and the number of TRAb-negative patients 
may not reflect the true frequency of TRAb-negative 
patients among the patients with GD. Secondly, 
because our study was retrospective, we could not 
assess thyroid-stimulating immunoglobulin levels in 
TRAb-negative patients with GD. Thirdly, the GO was 
not assessed according to the current guidelines, and 
we could not determine the association between the 
severity scores of the GO and TRAb levels. And finally, 
the goiter sizes of the participants were assessed by 
manual palpation rather than the assessment of the 
thyroid volume by ultrasonography. Although all 
patients admitted for hyperthyroidism in our center 
undergo thyroid ultrasonography and color-Doppler 
ultrasonography, the thyroid volume is not measured 
routinely in all patients. Therefore, we could not assess 
the relationship between TRAb and thyroid volume. 
However, the strength of this study derives from the in-
clusion of a large number of patients, particularly a large 
number of TRAb-negative GD patients with appropriate 
clinical and laboratory data. Therefore, we believe that 
our study is a clear example of daily practice.
Conclusions
Results from this study suggest TRAb levels at the initial 
diagnosis of GD are differently associated with clinical 
and laboratory parameters. Male patients and smoking 
patients with GD tended to have significantly higher 
TRAb levels at the initial diagnosis and more severe 
clinical hyperthyroidism. Furthermore, smoking male 
patients tended to have markedly higher TRAb levels 
compared to all other patients. TRAb-negative GD pa-
tients tended to have significantly less severe clinical 
and biochemical hyperthyroidism compared to patients 
with high TRAb levels. However, the smoking habit 
was also significantly lower among TRAb-negative GD 
patients. Therefore, our study results suggest that be-
sides the other factors, male gender and smoking habit 
may affect TRAb levels and consequently the severity 
of hyperthyroidism in patients with GD. Furthermore, 
male gender and smoking may have a synergistic effect 
on TRAb levels and consequently on the severity of 
hyperthyroidism in patients with GD. Further studies 
are required to confirm our results.
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